Cargando…
Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
SIMPLE SUMMARY: Non-small cell lung cancer is the most common type of lung cancer. Anaplastic Lymphoma Kinase (ALK) rearrangements have been found in 5–6% of non-small cell lung cancers. While ALK rearranged non-small cell lung cancer is exquisitely sensitive to ALK directed targeted therapies, it i...
Autores principales: | Sankar, Kamya, Nagrath, Sunitha, Ramnath, Nithya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004790/ https://www.ncbi.nlm.nih.gov/pubmed/33806977 http://dx.doi.org/10.3390/cancers13061476 |
Ejemplares similares
-
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
por: Zhang, Zhuo, et al.
Publicado: (2015) -
Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection
por: Murlidhar, Vasudha, et al.
Publicado: (2016) -
Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022) -
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021) -
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)